← Back to Search

Carbonic Anhydrase Inhibitor

Multiple Interventions for Orthostatic Intolerance

Phase 1 & 2
Waitlist Available
Led By Satish R Raj, MD MSCI
Research Sponsored by Satish R. Raj
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2h, 4h
Awards & highlights

Study Summary

This trial is testing different medications to see which one is best at controlling heart rate and improving symptoms of orthostatic intolerance.

Who is the study for?
This trial is for people who've felt dizzy or had a rapid heartbeat when standing up, lasting more than 6 months. It's not suitable for those with severe conditions like cancer or heart disease, or if they're taking drugs that could make their symptoms worse.Check my eligibility
What is being tested?
The study tests various treatments including medications like Octreotide and Propranolol, lifestyle aids such as abdominal binders, and other approaches to manage rapid heartbeat and discomfort upon standing in patients with orthostatic intolerance.See study design
What are the potential side effects?
Possible side effects from the treatments may include digestive changes, blood pressure fluctuations, sleep disturbances with melatonin, headache or dizziness from Midodrine, fatigue from Modafinil, and skin reactions at injection sites.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2h, 4h
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 2h, 4h for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Increase in heart rate with standing
Secondary outcome measures
Blood pressure
Decrease in blood pressure with standing
Orthostatic symptoms score
+2 more

Trial Design

20Treatment groups
Experimental Treatment
Placebo Group
Group I: Abdominal BinderExperimental Treatment1 Intervention
Abdominal binder with inflatable pressure over abdomen
Group II: 9Experimental Treatment1 Intervention
Memantine
Group III: 8Experimental Treatment1 Intervention
Mecamylamine
Group IV: 7Experimental Treatment1 Intervention
Isosorbide Dinitrate
Group V: 6Experimental Treatment1 Intervention
Indomethacin
Group VI: 5Experimental Treatment2 Interventions
Entacapone
Group VII: 4Experimental Treatment1 Intervention
Clonidine
Group VIII: 3Experimental Treatment1 Intervention
NO Drug
Group IX: 2Experimental Treatment2 Interventions
Atomoxetine
Group X: 19Experimental Treatment1 Intervention
Dead Space Breathing Device
Group XI: 18Experimental Treatment1 Intervention
Drinking Water
Group XII: 17Experimental Treatment1 Intervention
Normal Saline (0.9%) 1 liter
Group XIII: 16Experimental Treatment1 Intervention
Sertraline
Group XIV: 15Experimental Treatment4 Interventions
Propranolol
Group XV: 13Experimental Treatment1 Intervention
Octreotide
Group XVI: 12Experimental Treatment2 Interventions
Modafinil
Group XVII: 11Experimental Treatment1 Intervention
Midodrine
Group XVIII: 10Experimental Treatment1 Intervention
Melatonin
Group XIX: 1Experimental Treatment1 Intervention
Acetazolamide
Group XX: 14Placebo Group1 Intervention
Placebo (lactose tablet)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Propranolol
FDA approved
Octreotide
FDA approved
Memantine
FDA approved
Melatonin
2014
Completed Phase 4
~1150
Midodrine
FDA approved
Modafinil
FDA approved
Abdominal binder
2010
N/A
~120
Acetazolamide
FDA approved
Atomoxetine
FDA approved
Clonidine
FDA approved
Entacapone
FDA approved
Indomethacin
FDA approved
Mecamylamine
FDA approved
Isosorbide dinitrate
FDA approved
Sertraline
FDA approved
IV Saline
2016
Completed Phase 4
~180

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Institutes of Health (NIH)NIH
2,678 Previous Clinical Trials
6,909,646 Total Patients Enrolled
3 Trials studying Orthostatic Intolerance
196 Patients Enrolled for Orthostatic Intolerance
Satish R. RajLead Sponsor
6 Previous Clinical Trials
380 Total Patients Enrolled
3 Trials studying Orthostatic Intolerance
300 Patients Enrolled for Orthostatic Intolerance
National Center for Advancing Translational Sciences (NCATS)NIH
315 Previous Clinical Trials
387,682 Total Patients Enrolled

Media Library

Acetazolamide (Carbonic Anhydrase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00262470 — Phase 1 & 2
Orthostatic Intolerance Research Study Groups: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, Abdominal Binder
Orthostatic Intolerance Clinical Trial 2023: Acetazolamide Highlights & Side Effects. Trial Name: NCT00262470 — Phase 1 & 2
Acetazolamide (Carbonic Anhydrase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00262470 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the requirements to qualify for participation in this research?

"This trial is designed for people who suffer from tachycardia and are between 18-70 years old. In total, the researchers need 150 participants."

Answered by AI

Are geriatric patients being accepted into this trial?

"According to the information available, people aged 18-70 are eligible to apply for this clinical trial. There are 57 similar studies for those under 18 and 230 for patients over 65."

Answered by AI

Is this study enrolling new participants at this time?

"This trial is not currently active. The last update to the listing was on September 12th, 2022. There are 132 other trials for tachycardia and 174 studies involving Breathing Devices that are actively recruiting patients right now."

Answered by AI

What sorts of respiratory problems does this Breathing Device help with?

"bursitis is most commonly treated with Breathing Device. Breathing Device can also be useful for treating other conditions like Alzheimer's disease, migraines, dementia, and vascular conditions."

Answered by AI

How many individuals are allowed to join this experiment?

"Unfortunately, this specific trial is not currently seeking patients. However, there are 132 other trials related to tachycardia and 174 studies involving Breathing Devices that are actively recruiting participants."

Answered by AI

Are there other instances of research being done with this Breathing Device?

"There are 174 live clinical trials testing Breathing Devices, with 42 of those in Phase 3. Geneva, Illinois is one location where these devices are being tested, but there are 1,510 total locations for this type of trial."

Answered by AI
Recent research and studies
~9 spots leftby Dec 2025